At a glance
ClinicalIndex Comparison RecordPhase 2Active· 21 enrolled
Drug / intervention
Amivantamabdrug
Likely dose
Amivantamab 1050mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma
In Brief
A Phase 2 clinical trial evaluating Amivantamab for Salivary Gland Cancer. Active but no longer recruiting, targeting 21 participants across 5 sites.
Detailed Summary
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSalivary Gland Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
2022202320242025202620272028
First PostedOct 2021
Enrollment StartAug 2022
Primary CompletionMar 2026
TodayJul 2026
Study CompletionAug 2028
First PostedOct 12, 2021
Enrollment StartAug 5, 2022
Primary CompletionMar 2, 2026
Study CompletionAug 5, 2028
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.7 years ago
Interventions
Amivantamabdrug
Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).